• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Latest CATIE results: Atypicals no better than Trilafon for improving cognition

Latest CATIE results: Atypicals no better than Trilafon for improving cognition

July 1, 2007
Jesse H. Wright, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Jesse H. Wright, MD. Professor and Chief of Adult Psychiatry, University of Louisville School of Medicine, Co-author, Learning Cognitive Behavior Therapy: An Illustrated Guide.

Dr. Wright has disclosed that he receives royalities from books he has written about cognitive behavioral therapy.
                

Subject:
Antipsychotics

Short Description:
Latest CATIE results: Atypicals no better than Trilafon for improving cognition

Background:
One of the final major questions that the NIMH-funded CATIE trials promised to answer was whether atypical antipsychotics are better at improving cognition in schizophrenia than conventional agents, as some smaller studies implied. Patients with schizophrenia were randomly assigned to double blind treatment with Trilafon, Risperdal, Zyprexa, Seroquel, or Geodon. The patients were given neurocognitive testing at baseline and after 2, 6, and 18 months of treatment. Comparing the two scores showed that all treatments produced small neurocognitive improvement, with no significant differences among treatments. However, after 18 months, Trilafon was superior to the other agents in some secondary measures (Keefe R et al., Arch Gen Psychiatry 2007;64:633-647).

TCPR's Take:
This finding is not terribly surprising. The earlier studies showing apparent cognitive superiority of some atypicals used high dose Haldol as the comparator conventional agent, which often requires the use of anticholinergics to quell extrapyramidal side effects. Anticholinergics can cause confusion, which always made Haldol look worse in these studies. This confounding artifact was not present in CATIE, because investigators chose Trilafon, a medium potency drug that rarely requires the addition of anticholinergics.

General Psychiatry
KEYWORDS antipsychotics
Jesse H. Wright, MD

Is divorce a risk factor for getting a stimulant prescription?

More from this author
www.thecarlatreport.com
Issue Date: July 1, 2007
SUBSCRIBE NOW
Table Of Contents
Does Psychotherapy Work?
Psychotherapy: A Practical and Integrative Approach
High Yield Cognitive-Behavior Therapy Techniques
Zoloft not helpful for subsyndromal symptoms in cancer patients
More evidence that antipsychotics are dangerous in dementia
Is divorce a risk factor for getting a stimulant prescription?
Latest CATIE results: Atypicals no better than Trilafon for improving cognition
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.